Related Experiment Video
Updated: May 5, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Genistein and Butein as Bioactive Polyphenols: Molecular Targets, Metabolic Regulation, and Mechanistic Insights
Moon-Kyun Cho1,2, Yeji Lee3, Ki Dam Kim2
1Division of Molecular Cancer Research, Soonchunhyang Medical Research Institute, Soonchunhyang University, Cheonan 31511, Republic of Korea.
Abstract:
Bioactive polyphenols are increasingly recognized as modulators of multiple biological processes relevant to human health and disease. Among these compounds, genistein, a soy-derived isoflavone, and butein, a naturally occurring chalcone, have been investigated for their anticancer, anti-inflammatory, and metabolic regulatory activities, primarily in in vitro and preclinical experimental models. Despite their distinct chemical structures, available evidence indicates that genistein and butein can influence key molecular pathways involved in cell survival, energy metabolism, and programmed cell death. Experimental studies have shown that these compounds may modulate PI3K/Akt and MAPK/ERK signaling, alter glycolytic and mitochondrial metabolism, and induce apoptotic responses through caspase activation and poly(ADP-ribose) polymerase cleavage. This review provides a comprehensive overview of the chemical characteristics, bioavailability, and proposed molecular mechanisms of action of genistein and butein, with a particular focus on their potentially convergent roles in metabolic reprogramming and apoptotic signaling networks. In addition, we discuss the conceptual basis for combination approaches involving these compounds, emphasizing systems-level pathway modulation rather than definitive pharmacological synergy. Importantly, many of the reported biological effects have been observed under experimental conditions using concentrations that may exceed physiologically achievable concentrations, thereby limiting direct extrapolation to clinical settings. Furthermore, the current evidence base is constrained by limited in vivo validation and a lack of robust clinical data, particularly for butein. Future studies are required to better define pharmacokinetic properties, physiological relevance, and context-dependent biological effects, thereby providing a more rigorous framework for future evaluation of the translational potential of genistein and butein.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Epigenetic Regulation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Metabolism: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...

